ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to Glecaprevir/ Pibrentasvir

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03123965
Expanded Access Status : Available
First Posted : April 21, 2017
Last Update Posted : March 14, 2018
Sponsor:
Information provided by (Responsible Party):
AbbVie

April 18, 2017
April 21, 2017
March 14, 2018
 
Expanded Access to Glecaprevir/ Pibrentasvir
Expanded Access to Glecaprevir/ Pibrentasvir
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Not Provided
Expanded Access
Individual Patients
Hepatitis C Virus Infection
  • Drug: glecaprevir
    It will be administered orally.
    Other Name: ABT-493
  • Drug: pibrentasvir
    It will be administered orally.
    Other Name: ABT-530
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Available
Not Provided
Not Provided
Child, Adult, Older Adult
Contact: AbbVie_Call Center 847-283-8955 abbvieclinicaltrials@abbvie.com
Not Provided
 
 
NCT03123965
C16-563
AbbVie
AbbVie
Not Provided
Study Director: AbbVie Inc. AbbVie
AbbVie
March 2018